drugset / Trial / NCT06549751
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Phase 1
Not yet recruiting
38 enrolled
Marker Therapeutics, Inc.
M.D. Anderson Cancer Center · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this clinical trial is to assess safety and tolerability of escalating doses of MT-601 administered during the off week of chemotherapy regimen for patients with pancreatic cancer. The main question\[s\] it aims to answer are: safety and efficacy • overall response rate and duration of response. Participants will meet all applicable inclusion criteria prior to chemotherapy and must agree to provide apheresis material.
Timeline
- Start
- 2026-07-16
- Primary completion
- 2028-07-16
- Completion
- 2028-09-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NELDALEUCEL | Cell therapy | 2e+08 cells | Intravenous |
| Subject | NELDALEUCEL | Cell therapy | 4e+08 cells | Intravenous |
| Subject | NELDALEUCEL | Cell therapy | 8e+08 cells | Intravenous |
| Subject | NELDALEUCEL | Cell therapy | 1.2e+09 cells | Intravenous |